Bei Wang

Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism

Ben‐Quan Shen, Daniela Bumbaca, Ola M. Saad et al. · Current Drug Metabolism · 2012 · 137 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer

Manish Gupta, Patricia LoRusso, Bei Wang et al. · The Journal of Clinical Pharmacology · 2011 · 70 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Manish Gupta, Bei Wang, Timothy J. Carrothers et al. · Clinical Pharmacology in Drug Development · 2013 · 39 citations

Medicine, Oncology, Pharmacology +17

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal et al. · The Journal of Clinical Pharmacology · 2018 · 37 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

Chunze Li, Bei Wang, Shang‐Chiung Chen et al. · Cancer Chemotherapy and Pharmacology · 2017 · 30 citations

Medicine, Oncology, Pharmacology +16